the efficacy and safety of fluoxetine delayed-release 90 mg/weekly in psychiatry: an evidence-based mini-review

Context: fluoxetine, a selective serotonin reuptake inhibitor (ssri), is widely used in the treatment of various psychiatric disorders. while the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. this mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. evidence acquisition: a comprehensive literature search was conducted using electronic databases (pubmed and embase) to identify relevant studies published until july 2023. studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. the identified studies were critically appraised for their methodology and quality. results: limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. however, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (mdd), obsessive-compulsive disorder (ocd), premature ejaculation, and premenstrual dysphoric disorder. these studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. conclusions: once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.